216 related articles for article (PubMed ID: 30992168)
21. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
22. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.
Ruymann FB; Grovas AC
Cancer Invest; 2000; 18(3):223-41. PubMed ID: 10754991
[TBL] [Abstract][Full Text] [Related]
23. Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma.
Harel M; Ferrer FA; Shapiro LH; Makari JH
Urol Oncol; 2016 Feb; 34(2):103-15. PubMed ID: 26519985
[TBL] [Abstract][Full Text] [Related]
24. Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
Chisholm J; Mandeville H; Adams M; Minard-Collin V; Rogers T; Kelsey A; Shipley J; van Rijn RR; de Vries I; van Ewijk R; de Keizer B; Gatz SA; Casanova M; Hjalgrim LL; Firth C; Wheatley K; Kearns P; Liu W; Kirkham A; Rees H; Bisogno G; Wasti A; Wakeling S; Heenen D; Tweddle DA; Merks JHM; Jenney M
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473359
[TBL] [Abstract][Full Text] [Related]
25. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
[TBL] [Abstract][Full Text] [Related]
26. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
[TBL] [Abstract][Full Text] [Related]
27. Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy.
Viswanathan AN; Grier HE; Litman HJ; Perez-Atayde A; Tarbell NJ; Neuberg D; Shamberger RC; Marcus KJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1208-14. PubMed ID: 15001265
[TBL] [Abstract][Full Text] [Related]
28. Paediatric nasopharyngeal rhabdomyosarcoma: A case series and literature review.
Healy JN; Borg MF
J Med Imaging Radiat Oncol; 2010 Aug; 54(4):388-94. PubMed ID: 20718921
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapy for rhabdomyosarcoma: indications and outcome.
Terezakis SA; Wharam MD
Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):27-35. PubMed ID: 22990007
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of combined surgery and brachytherapy approaches for children and young people with relapsed and refractory rhabdomyosarcoma (Local-REFoRMS).
Ballantyne E; Evans C; Shepherd L; Fulbright H; Wakeling S; Phillips B; Morgan JE
Pediatr Blood Cancer; 2024 Jun; 71(6):e30952. PubMed ID: 38566349
[TBL] [Abstract][Full Text] [Related]
31. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
[TBL] [Abstract][Full Text] [Related]
32. Local tumor control in rhabdomyosarcoma following low-dose irradiation: comparison of group II and select group III patients.
Regine WF; Fontanesi J; Kumar P; Ayers D; Bowman LC; Pappo AS; Coffey DH; Avery L; Rao BN; Kun LE
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):485-91. PubMed ID: 7852110
[TBL] [Abstract][Full Text] [Related]
33. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group.
Raney RB; Asmar L; Vassilopoulou-Sellin R; Klein MJ; Donaldson SS; Green J; Heyn R; Wharam M; Glicksman AS; Gehan EA; Anderson J; Maurer HM
Med Pediatr Oncol; 1999 Oct; 33(4):362-71. PubMed ID: 10491544
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial evaluating selective use of altered radiation dose and fractionation in patients with unresectable rhabdomyosarcoma.
Regine WF; Fontanesi J; Kumar P; Zeitzer K; Greenwald C; Bowman L; Shapiro DN; Rao BN; Kun LE
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):799-805. PubMed ID: 7860391
[TBL] [Abstract][Full Text] [Related]
35. Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma.
Chargari C; Haie-Meder C; Guérin F; Minard-Colin V; de Lambert G; Mazeron R; Escande A; Marsolat F; Dumas I; Deutsch E; Valteau-Couanet D; Audry G; Oberlin O; Martelli H
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):352-359. PubMed ID: 28463154
[TBL] [Abstract][Full Text] [Related]
36. Long-term disease-free survival following salvage brachytherapy for recurrent pediatric rhabdomyosarcoma: Two case reports and review of relevant literature.
Aghili M; Kolahdouzan K; Shabani M; Jafari F; Jaberi R
Brachytherapy; 2022; 21(4):494-500. PubMed ID: 35514002
[TBL] [Abstract][Full Text] [Related]
37. [Pediatric rhabdomyosarcoma of the infratemporal fossa].
Rozan O; Janot F; Oberlin O; Schwaab G; Quintana E; Tran Ba Huy P; Georges B; Luboinski B
Ann Otolaryngol Chir Cervicofac; 2002 Sep; 119(4):195-201. PubMed ID: 12410115
[TBL] [Abstract][Full Text] [Related]
38. [Role of radiotherapy in combined therapy of soft tissue sarcoma in children and adolescents].
Golubicić I; Nikitović M; Bokun J; Gavrilović D; Radosević-Jelić Lj
Srp Arh Celok Lek; 2000; 128(5-6):172-8. PubMed ID: 11089417
[TBL] [Abstract][Full Text] [Related]
39. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma.
Boulad F; Kernan NA; LaQuaglia MP; Heller G; Lindsley KL; Rosenfield NS; Abramson SJ; Gerald WL; Small TN; Gillio AP; Gulati SC; O'Reilly RJ; Ghavimi F
J Clin Oncol; 1998 May; 16(5):1697-706. PubMed ID: 9586881
[TBL] [Abstract][Full Text] [Related]
40. Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma.
Smith SC; Lindsley SK; Felgenhauer J; Hawkins DS; Douglas JG
J Pediatr Hematol Oncol; 2003 Oct; 25(10):774-9. PubMed ID: 14528099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
